Milademetan
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Trial Timeline
Aug 23, 2018 → Sep 11, 2019
NCT ID
NCT03671564About Milademetan
Milademetan is a phase 1 stage product being developed by Daiichi Sankyo for Acute Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03671564. Target conditions include Acute Myeloid Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03671564 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia